Rossi, Federica Maria
 Distribuzione geografica
Continente #
NA - Nord America 287
EU - Europa 190
AS - Asia 31
Totale 508
Nazione #
US - Stati Uniti d'America 287
SE - Svezia 87
IT - Italia 46
IE - Irlanda 23
SG - Singapore 14
FR - Francia 11
GB - Regno Unito 8
IN - India 6
RU - Federazione Russa 6
CN - Cina 5
DE - Germania 5
KR - Corea 3
HK - Hong Kong 2
DK - Danimarca 1
HR - Croazia 1
IR - Iran 1
PT - Portogallo 1
UA - Ucraina 1
Totale 508
Città #
Chandler 95
New York 29
Ashburn 23
Dublin 17
San Mateo 12
Marseille 10
Princeton 10
Milan 9
Singapore 9
Wilmington 8
Florence 6
Turin 6
Cattolica 5
Huddersfield 5
Pune 5
Boston 4
Dallas 4
Vicopisano 4
Fairfield 3
Falls Church 3
Genoa 3
Moscow 3
Norwalk 3
Seoul 3
Andover 2
Fremont 2
Garden City 2
Hong Kong 2
Houston 2
Redwood City 2
Seattle 2
Tarquinia 2
Verona 2
Washington 2
Beijing 1
Berlin 1
Bremen 1
Conegliano 1
Cormeilles-en-Parisis 1
Genova 1
Gurgaon 1
Hefei 1
Hounslow 1
Kish 1
Ladispoli 1
Lisbon 1
Mountain View 1
Padova 1
Parma 1
Pomigliano D'arco 1
Rowlands Castle 1
Saint Petersburg 1
Secaucus 1
Trecase 1
Woodbridge 1
Zagreb 1
Totale 321
Nome #
Public investment trends across levels of government in Italy 68
Assessment of the 4-factor score: Retrospective analysis of 586 CLL patients receiving ibrutinib. A campus CLL study 58
Comparison of ibrutinib and idelalisib plus rituximab in real-life relapsed/resistant chronic lymphocytic leukemia cases 55
Survival risk score for real-life relapsed/refractory chronic lymphocytic leukemia patients receiving ibrutinib. A campus CLL study 51
Comparison between sedation room and operating room in central venous catheter positioning in children 49
SF3B1-mutated chronic lymphocytic leukemia shows evidence of NOTCH1 pathway activation including CD20 downregulation 46
CD49d promotes disease progression in chronic lymphocytic leukemia: New insights from CD49d bimodal expression 44
Effectiveness of ibrutinib as first-line therapy for chronic lymphocytic leukemia patients and indirect comparison with rituximab-bendamustine: Results of study on 486 cases outside clinical trials 41
TP53 disruption as a risk factor in the era of targeted therapies: A multicenter retrospective study of 525 chronic lymphocytic leukemia cases 39
Validation of a survival-risk score (SRS) in relapsed/refractory CLL patients treated with idelalisib–rituximab 32
The time to first treatment is an independent predictor of overall survival in chronic lymphocytic leukemia 21
Clinical impact of TP53 disruption in chronic lymphocytic leukemia patients treated with ibrutinib: a campus CLL study 18
Totale 522
Categoria #
all - tutte 3.187
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 3.187


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/202119 0 0 0 0 14 1 1 1 0 0 1 1
2021/2022142 0 0 35 22 18 3 2 17 6 2 27 10
2022/2023220 29 31 17 31 10 30 11 15 32 0 11 3
2023/2024132 6 25 6 9 11 45 3 7 1 4 5 10
2024/20259 5 4 0 0 0 0 0 0 0 0 0 0
Totale 522